These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 31199173)

  • 21. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
    N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
    Reich K; Armstrong AW; Foley P; Song M; Miller M; Shen YK; You Y; Han C; Gordon KB
    Am J Clin Dermatol; 2020 Dec; 21(6):881-890. PubMed ID: 32910434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
    Blauvelt A; Burge R; Malatestinic W; Brnabic A; Guo J; Janardhanan M; Zhu B
    J Manag Care Spec Pharm; 2021 Jan; 27(1):84-94. PubMed ID: 33377444
    [No Abstract]   [Full Text] [Related]  

  • 24. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
    Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
    Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
    Reich K; Papp KA; Armstrong AW; Wasfi Y; Li S; Shen YK; Randazzo B; Song M; Kimball AB
    Br J Dermatol; 2019 May; 180(5):1039-1049. PubMed ID: 30485400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1.
    Griffiths CEM; Papp KA; Song M; Miller M; You Y; Shen YK; Han C; Blauvelt A
    J Dermatolog Treat; 2022 Mar; 33(2):848-856. PubMed ID: 32660282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2.
    Reich K; Song M; Li S; Jiang J; Youn SW; Tsai TF; Choe YB; Huang YH; Gordon KB
    J Dermatol; 2019 Dec; 46(12):1141-1152. PubMed ID: 31631377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis.
    Feldman SR; Foster SA; Zhu B; Burge R; Al Sawah S; Goldblum OM
    J Drugs Dermatol; 2017 Dec; 16(12):1246-1252. PubMed ID: 29240860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials.
    Yang J; Wang Z; Zhang X
    J Immunol Res; 2020; 2020():4975628. PubMed ID: 32724829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
    Tillett W; Egeberg A; Sonkoly E; Gorecki P; Tjärnlund A; Buyze J; Wegner S; McGonagle D
    Arthritis Res Ther; 2023 Sep; 25(1):169. PubMed ID: 37715294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
    Reich K; Gordon KB; Strober BE; Armstrong AW; Miller M; Shen YK; You Y; Han C; Yang YW; Foley P; Griffiths CEM
    Br J Dermatol; 2021 Dec; 185(6):1146-1159. PubMed ID: 34105767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab for the treatment of psoriasis.
    Turner D; Picot J; Cooper K; Loveman E
    Health Technol Assess; 2009 Sep; 13 Suppl 2():49-54. PubMed ID: 19804689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
    Xue W; Saharia P; Gray E; Khoudigian-Sinani S; Gaudet V; Barbeau M; Papp K
    J Cutan Med Surg; 2020; 24(6):561-572. PubMed ID: 32588642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.
    Al-Salama ZT; Scott LJ
    Am J Clin Dermatol; 2018 Dec; 19(6):907-918. PubMed ID: 30467781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bimekizumab versus Adalimumab in Plaque Psoriasis.
    Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
    N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
    Papp KA; Blauvelt A; Kimball AB; Han C; Randazzo B; Wasfi Y; Shen YK; Li S; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1515-1522. PubMed ID: 29512196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study.
    Li N; Teeple A; Muser E; You Y; Song M; Armstrong AW
    J Dermatolog Treat; 2022 Feb; 33(1):278-283. PubMed ID: 32233940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.